Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area.
about
Localization and function of the cannabinoid CB1 receptor in the anterolateral bed nucleus of the stria terminalisHub and switches: endocannabinoid signalling in midbrain dopamine neuronsNeuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like StimulantsTo Act or Not to Act: Endocannabinoid/Dopamine Interactions in Decision-MakingCocaine-Induced Endocannabinoid Mobilization in the Ventral Tegmental AreaEndocannabinoid signalling in reward and addiction.Endocannabinoids shape accumbal encoding of cue-motivated behavior via CB1 receptor activation in the ventral tegmentum.Release of endogenous cannabinoids from ventral tegmental area dopamine neurons and the modulation of synaptic processesAfferent-specific AMPA receptor subunit composition and regulation of synaptic plasticity in midbrain dopamine neurons by abused drugs.Cannabinoid modulation of the dopaminergic circuitry: implications for limbic and striatal output.Multiple functions of endocannabinoid signaling in the brain.Architecture of cannabinoid signaling in mouse retinaCannabinoid modulation of drug reward and the implications of marijuana legalizationDrug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light.Striatal dopamine neurotransmission: regulation of release and uptakeOrexin/hypocretin role in reward: implications for opioid and other addictionsDiacylglycerol lipase-alpha and -beta control neurite outgrowth in neuro-2a cells through distinct molecular mechanisms.Extracellular signal-regulated kinase signaling in the ventral tegmental area mediates cocaine-induced synaptic plasticity and rewarding effects.Role of the endogenous cannabinoid system in nicotine addiction: novel insights.Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotectionNeural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteersEndocannabinoid signaling and long-term synaptic plasticity.Chronic adolescent exposure to delta-9-tetrahydrocannabinol in COMT mutant mice: impact on indices of dopaminergic, endocannabinoid and GABAergic pathways.Chronic Δ⁹-tetrahydrocannabinol exposure induces a sensitization of dopamine D₂/₃ receptors in the mesoaccumbens and nigrostriatal systems.Ventral tegmental area dopamine and GABA neurons: Physiological properties and expression of mRNA for endocannabinoid biosynthetic elements.Endocannabinoid-mediated long-term depression of afferent excitatory synapses in hippocampal pyramidal cells and GABAergic interneurons.Cannabinoids and value-based decision making: implications for neurodegenerative disorders.Cannabinoid-1 receptors in the mouse ventral pallidum are targeted to axonal profiles expressing functionally opposed opioid peptides and contacting N-acylphosphatidylethanolamine-hydrolyzing phospholipase D terminals.Complementary synaptic distribution of enzymes responsible for synthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in the human hippocampusAltered dendritic distribution of dopamine D2 receptors and reduction in mitochondrial number in parvalbumin-containing interneurons in the medial prefrontal cortex of cannabinoid-1 (CB1) receptor knockout miceAttenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout miceOrexins contribute to restraint stress-induced cocaine relapse by endocannabinoid-mediated disinhibition of dopaminergic neurons.Molecular architecture of endocannabinoid signaling at nociceptive synapses mediating analgesia.Endocannabinoid-mediated control of synaptic transmission.More surprises lying ahead. The endocannabinoids keep us guessing.Insights to drug addiction derived from ultrastructural views of the mesocorticolimbic system.Regulation of striatal dopamine release by presynaptic auto- and heteroreceptors.Tales from the dark side: do neuromodulators of drug withdrawal require changes in endocannabinoid tone?What can we learn about schizophrenia from studying the human model, drug-induced psychosis?No more pain upon Gq-protein-coupled receptor activation: role of endocannabinoids.
P2860
Q21142667-E61B0C22-B9D9-4445-A313-129ADF89DA6CQ24623244-35D8C0F1-999D-432A-A157-665D5776EAB2Q26752739-E5C7814B-8161-42F6-AC22-876E9A9BE184Q26770739-21EE42AB-183C-498B-B9D1-BA3D412408C5Q27320220-329490A6-C34F-4047-A556-6F2B192C7A13Q30373359-10864FD6-FFA0-4998-9AC0-62436BA1F114Q30504551-E5355715-356E-4D15-8583-26325B28035BQ33599036-C1770CE6-FE86-4A63-9049-C9DCF5D28AEEQ33975305-7C465327-521C-4201-A943-14CDEAAEB72EQ34248777-A7746C4F-0467-444A-956B-EF584278D80FQ34270199-D15DD28D-514A-463C-819C-7A969AA46B5AQ34313968-972123ED-68B2-49DD-9AE0-6008718411EDQ34451442-FE21B757-85CE-4CC4-A356-52DD0F9CEA03Q34509725-C7AF905A-35C0-42C9-B6EF-788D7B7668CEQ34524803-503F4AB0-E153-4C65-8D5B-1898A11A1FC2Q34939568-A3D2CAC4-5861-4A53-8DD0-EED02BCA6258Q35080503-FDBA31C4-F768-445D-94F0-37FEB0961EF5Q35155391-0710D238-9386-4D6F-919D-8CE2F9B4D47BQ35216481-8368D723-60CB-4109-945C-CAE9B017C86EQ35499568-7EAB80DA-6DF2-4B15-AF3E-C70ED1B5DC48Q35626920-66E8EDA0-EEBA-4DE2-B78B-771BBD5E19D7Q35679432-C899671E-C745-472D-A5AD-DA22FC8A0B63Q35982298-EF2AE812-32D2-4305-9C48-34ABABECB542Q36234294-72B9EB74-FCC2-46D1-BB5D-0A01035235FAQ36265810-F9B4F8F9-59A5-42C0-A23B-91B1DE339ED4Q36389209-51BBBC8A-86C7-44FB-8010-3E3C13A6E878Q36393644-ECEEDEE4-8F41-4CC7-AB66-C3160B44142DQ36395211-35513EB2-C6B9-4A6B-A44E-3599B44089B9Q36917918-D338F8C6-9D4F-4EB1-82A8-4E2A45789844Q36937690-7846188C-C45A-4CEB-A933-1B0ED7112579Q37060812-3306A54C-B4F5-4524-9295-29C764BB03E3Q37128023-8628596F-87F6-4E50-B727-44C7FF7C2095Q37216017-0C2934C0-2947-4EB4-A2B5-41EA6EB029DCQ37363621-11B23DB1-0A6C-4F46-93CB-81164DAA5BA6Q37373721-1168312A-EAF0-4E2B-82FF-19C50D691C27Q37968615-1BB26A8B-C3DE-41E7-A7E3-229C4CDB1B9DQ38019926-A212BAA0-93AF-408C-9B56-1417F7F4047FQ38126265-A64281B5-516D-4F9A-A182-30AE2FD938B2Q38153344-1E2B333C-634E-4028-A6E8-1D6023320E3AQ38185075-3DF2E7F1-148C-4C3C-9673-8E571B935A4A
P2860
Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Identification of the sites of ...... in the ventral tegmental area.
@ast
Identification of the sites of ...... in the ventral tegmental area.
@en
type
label
Identification of the sites of ...... in the ventral tegmental area.
@ast
Identification of the sites of ...... in the ventral tegmental area.
@en
prefLabel
Identification of the sites of ...... in the ventral tegmental area.
@ast
Identification of the sites of ...... in the ventral tegmental area.
@en
P2093
P2860
P1433
P1476
Identification of the sites of ...... in the ventral tegmental area
@en
P2093
Andreas Zimmer
Ferenc Mátyás
Gabriella M Urbán
Masahiko Watanabe
Tamás F Freund
P2860
P304
P356
10.1016/J.NEUROPHARM.2007.05.028
P577
2007-06-22T00:00:00Z